Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic‐Pharmacokinetic Prospective Multicenter Study-Reference-Cited by-同舟云学术

Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic‐Pharmacokinetic Prospective Multicenter Study

Published:2020-01 Issue:1 Volume:40 Page:17-25
ISSN:0277-0008
Container-title:Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
language:en
Short-container-title:Pharmacotherapy

Author:

Blanco‐Dorado Sara¹²³^ORCID,Maroñas Olalla⁴⁵,Latorre‐Pellicer Ana⁴,Rodríguez Jato María Teresa¹,López‐Vizcaíno Ana⁶,Gómez Márquez Aurea⁷,Bardán García Belén⁸,Belles Medall Dolores⁹,Barbeito Castiñeiras Gema¹⁰,Pérez del Molino Bernal María Luisa¹⁰,Campos‐Toimil Manuel³,Otero Espinar Francisco³,Blanco Hortas Andrés¹¹,Durán Piñeiro Goretti²^ORCID,Zarra Ferro Irene¹²,Carracedo Ángel⁴⁵,Lamas María Jesús²,Fernández‐Ferreiro Anxo¹²³

Affiliation:

1. Pharmacy Department University Clinical Hospital Santiago de Compostela (CHUS) Santiago de Compostela Spain

2. Clinical Pharmacology Group Health Research Institute of Santiago de Compostela (IDIS) University Clinical Hospital Santiago de Compostela Spain

3. Department of Pharmacology, Pharmacy and Pharmaceutical Technology Faculty of Pharmacy University of Santiago de Compostela (USC) Santiago de Compostela Spain

4. Genomic Medicine Group Centro Nacional de Genotipado (CEGEN‐PRB3) CIBERER CIMUS University of Santiago de Compostela (USC) Santiago de Compostela Spain

5. Galician Foundation of Genomic Medicine Health Research Institute of Santiago de Compostela (IDIS) SERGAS Santiago de Compostela Spain

6. Pharmacy Department University Hospital Lucus Augusti (HULA) Lugo Spain

7. Pharmacy Department University Hospital Ourense (CHUO) Ourense Spain

8. Pharmacy Department University Hospital Ferrol (CHUF) A Coruña Spain

9. Pharmacy Department General University Hospital Castellón (GVA) Castellon Spain

10. Microbiology Department University Clinical Hospital Santiago de Compostela (CHUS) Santiago de Compostela Spain

11. Epidemiology Unit Fundación Instituto de Investigación Sanitaria de Santiago de Compostela (FIDIS) University Hospital Lucus Augusti (HULA) Lugo Spain

Publisher

Wiley

Subject

Pharmacology (medical)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/phar.2351

Reference43 articles.

1. Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America

2. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America

3. Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis

4. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children

5. Voriconazole Therapeutic Drug Monitoring in Patients with Invasive Mycoses Improves Efficacy and Safety Outcomes

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Developments in pharmacogenetics, pharmacogenomics, and personalized medicine;Pharmacological Research;2024-02

2. The impact of gene polymorphism and hepatic insufficiency on voriconazole dose adjustment in invasive fungal infection individuals;Frontiers in Genetics;2023-08-24

3. Comment on ‘Therapeutic drug monitoring-guided treatment versus standard dosing of voriconazole for invasive aspergillosis in haematological patients: A multicentre, prospective, cluster randomised, crossover clinical trial’;International Journal of Antimicrobial Agents;2023-08

4. Recommendations on the use of azole antifungals in hematology-oncology patients;Revista Española de Quimioterapia;2023-04-05

5. Clinical Practice Guideline for the Therapeutic Drug Monitoring of Voriconazole in Non-Asian and Asian Adult Patients: Consensus Review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring;Clinical Therapeutics;2022-12